| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5475034 | HARROW EYE | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
Jun, 2014
(9 years ago) | |
| US8071648 | HARROW EYE | Topical nepafenac formulations |
Dec, 2025
(1 year, 7 months from now) | |
| US8324281 | HARROW EYE | Topical nepafenac formulations |
Dec, 2025
(1 year, 7 months from now) | |
| US7834059 | HARROW EYE | Topical nepafenac formulations |
Jan, 2027
(2 years from now) | |
Nevanac is owned by Harrow Eye.
Nevanac contains Nepafenac.
Nevanac has a total of 4 drug patents out of which 1 drug patent has expired.
Expired drug patents of Nevanac are:
- US5475034
Nevanac was authorised for market use on 19 August, 2005.
Nevanac is available in suspension/drops;ophthalmic dosage forms.
Nevanac can be used as method of treating ocular inflammation.
The generics of Nevanac are possible to be released after 31 January, 2027.
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 19 August, 2005
Treatment: Method of treating ocular inflammation
Dosage: SUSPENSION/DROPS;OPHTHALMIC
More Information on Dosage
NEVANAC family patents
